VBI-2902

VBI-2902
Vaccine description
Target	SARS-CoV-2
Vaccine type	Virus-like particles
Clinical data
Other names	VBI-2902a
Routes of; administration	Intramuscular

N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1]

History

In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[2] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[2] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[2][3][4] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[5]

References

Philippidis, Alex (1 November 2021). "Six Up-and-Coming COVID-19 Vaccines". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 December 2021.
"VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. 9 March 2021. Retrieved 22 March 2021.
"VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 March 2022.
VBI Vaccines Inc. (1 October 2021). "A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults". {{cite journal}}: Cite journal requires |journal= (help)
Curran M, Sali D, Kovessy P (August 2020). "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. Archived from the original on 2 May 2021. Retrieved 22 March 2021.

External links

https://www.vbivaccines.com/press-releases/vbi-2902-preclinical-and-challenge-study-data/

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[GEN_2021-11-01-1] Philippidis, Alex (1 November 2021). "Six Up-and-Coming COVID-19 Vaccines". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 December 2021.

[VBI_vaccines_20210309-2] "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. 9 March 2021. Retrieved 22 March 2021.

[3] "VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Retrieved 27 March 2022.

[4] VBI Vaccines Inc. (1 October 2021). "A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults". {{cite journal}}: Cite journal requires |journal= (help)

[BTH_202008-5] Curran M, Sali D, Kovessy P (August 2020). "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. Archived from the original on 2 May 2021. Retrieved 22 March 2021.